DS STAGE II MULTIPLE MYELOMA
Clinical trials for DS STAGE II MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new DS STAGE II MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for DS STAGE II MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Myeloma showdown: does adding a third drug boost survival?
Disease control OngoingThis phase 3 trial compares two treatment combinations for people newly diagnosed with multiple myeloma who are not planning an immediate stem cell transplant. One group gets lenalidomide plus low-dose dexamethasone, while the other gets those two drugs plus bortezomib. The goal …
Matched conditions: DS STAGE II MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 23, 2026 11:55 UTC
-
New hope for myeloma patients: drug may keep cancer at bay after transplant
Disease control OngoingThis study tested whether taking lenalidomide after a stem cell transplant helps keep multiple myeloma from coming back. About 460 patients who had a transplant received either lenalidomide or a placebo. The goal was to see if the drug could delay cancer progression. While lenali…
Matched conditions: DS STAGE II MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 22, 2026 12:08 UTC
-
New combo shows promise in myeloma battle
Disease control OngoingThis study tested two different doses of dexamethasone combined with lenalidomide in 452 people newly diagnosed with multiple myeloma. The goal was to see which dose worked better at shrinking tumors. If the first treatment didn't work, patients could switch to a thalidomide-base…
Matched conditions: DS STAGE II MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 22, 2026 12:06 UTC